NasdaqGS:OLMABiotechs
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans
Olema Pharmaceuticals (OLMA) is back on trader watchlists after recent analyst commentary around its breast cancer pipeline and management’s confirmation that key clinical milestones remain on schedule through 2026.
See our latest analysis for Olema Pharmaceuticals.
At a share price of US$25.72, Olema has eased back slightly in the last session, but its roughly 205% 90 day share price return and very large 1 year total shareholder return suggest momentum has been building as investors weigh...